Database : HANSEN
Search on : VACINAS BACTERIANAS [Subject descriptor]
References found : 39 [refine]
Displaying: 1 .. 20   in format [Detailed]

page 1 de 2 go to page        

  1 / 39 HANSEN  
              next record last record
select
to print
Id:17691
Author:Scollard, D. M; Adams, L. B; Gillis, T. P; Krahenbuhl, J. L; Truman, R. W; Williams, D. L
Title:The continuing challenges of leprosy ..-
Source:s.l; s.n; 2006. 44 p. ilus, tab.
Abstract:Leprosy is best understood as two conjoined diseases. The first is a chronic mycobacterial infection that elicits an extraordinary range of cellular immune responses in humans. The second is a peripheral neuropathy that is initiated by the infection and the accompanying immunological events. The infection is curable but not preventable, and leprosy remains a major global health problem, especially in the developing world, publicity to the contrary notwithstanding. Mycobacterium leprae remains noncultivable, and for over a century leprosy has presented major challenges in the fields of microbiology, pathology, immunology, and genetics; it continues to do so today. This review focuses on recent advances in our understanding of M. leprae and the host response to it, especially concerning molecular identification of M. leprae, knowledge of its genome, transcriptome, and proteome, its mechanisms of microbial resistance, and recognition of strains by variable-number tandem repeat analysis. Advances in experimental models include studies in gene knockout mice and the development of molecular techniques to explore the armadillo model. In clinical studies, notable progress has been made concerning the immunology and immunopathology of leprosy, the genetics of human resistance, mechanisms of nerve injury, and chemotherapy. In nearly all of these areas, however, leprosy remains poorly understood compared to other major bacterial diseases. (AU).
Descriptors:Antiinfecciosos/TU
Proteínas de Bactérias/ME
Vacinas Bacterianas
Modelos Animais de Doenças
Suscetibilidade à Doença/IM
Resistência Bacteriana a Drogas
Genes Bacterianos/GE
Predisposição Genética para Doença
Genoma Bacteriano
Imunidade Celular
Imunidade Natural/GE
Hansenostáticos/PD/TU
Hanseníase/*/DI/MI/TH
Mycobacterium leprae/*/CH/DE/IP/PH
Nervos Periféricos/MI
Doenças do Sistema Nervoso Periférico/MI/PA
Reação em Cadeia da Polimerase
Research Support, N.I.H., Extramural
Células de Schwann/IM/MI
Limits:HUMANO
ANIMAL
CAMUNDONGOS
SUPPORT, NON-U.S. GOV'T
Location:BR191.1; 09365/S


  2 / 39 HANSEN  
              first record previous record next record last record
select
to print
Id:13872
Author:Convit, Jacinto; Monzón, H; Pinardi, M. E; Aránzazu, N; Ulrich, M
Title:The development of an active vaccine against leprosy ..-
Source:s.l; s.n; 1979. 3 p. .
Abstract:The development of an effective vaccine against leprosy will be directed to obtain a product which can modify the immunological response of the population susceptible to develop the disease and to avoid the occurence of lepromatous, infecting forms. This action would interrupt the transmission chain, producing a important decrease in tge incidence of the disease. The measures used at present fotr anti-leprosy campaigns such as early diagnosis, control of contacts, out-patient treatment and prevention of disabilities, can be effective if applied with a high degree of efficiency and during extended periods of time. If to these measures we could add a vaccine, we would be able to reduce considerably the expense and time needes for keeping the disease under control. The development of a vaccine against leprosy is based on the assumption the disease is due to an immunological defect of the host which is specific against this particular bacterium. Previous work done by us, where we have obtained highly favorable immunological modifications in pre-lepromatous, indeterminate patients and in Mitsuda negative contacts and, partially, in lepromatous patients, using an injection of a mixture of armadillo M. leprae and BCG, serves as basis for our proposal of using this same type of preparation as an anti-leprosy vaccine in susceptible persons, where ity would evoke a positive immunological change which would prevent the onset of infecting forms of the disease.(AU).
Descriptors:VACINAS BACTERIANAS/admin
HANSENIASE/imunol
HANSENIASE/prev
MYCOBACTERIUM LEPRAE/imunol
VENEZUELA
Limits:HUMANO
Electronic Medium:http://www.ilsl.br
Location:BR191.1; 00575/s


  3 / 39 HANSEN  
              first record previous record next record last record
select
to print
Id:13735
Author:Ngamying, Maeya; Sawanpanyalert, Pathom; Butraporn, Raywadee; Nikasri, Junjira; Cho, Sang-Nae; Levy, Louis; Brennan, Patrick J
Title:Effect of vaccination with refined components of the organism on infection of mice with Mycobacterium leprae ..-
Source:s.l; s.n; 2003. 3 p. tab.
Abstract:Only native products of Mycobacterium leprae, whether cell wall, cytosol, or membrane derived, can confer protective immunity against challenge in the mouse footpad. Previously, recombinant proteins were shown to be ineffective. The cell wall skeleton-the mycolyl-arabinogalactan-peptidoglycan complex-devoid of proteins is not protective. (AU).
Descriptors:HANSENIASE/prev
VACINAS BACTERIANAS/imunol
ESQUELETO DA PAREDE CELULAR/imunol
CAMUNDONGOS ENDOGÂMICOS BALB C
MYCOBACTERIUM BOVIS/imunol
MYCOBACTERIUM LEPRAE/imunol
VACINACAO
Limits:ANIMAL
FEMININO
CAMUNDONGOS
SUPPORT, U.S. GOV'T, P.H.S.
Electronic Medium:http://www.ilsl.br
Location:BR191.1


  4 / 39 HANSEN  
              first record previous record next record last record
select
to print
Id:13474
Author:Shepard, Charles C; Van Landingham, Rosalind M; Walker, Laura L; Ye, Shang-Zhang
Title:Comparison of the immunogenicity of vaccines prepared from viable Mycobacterium bovis BCG, heat-killed Mycobacterium leprae, and a mixture of the two for normal and M. leprae-tolerant mice ..-
Source:s.l; s.n; jun. 1983. 8 p. graf.
Abstract:Intradermal vaccines consisting of viable Mycobacterium bovis BCG, heat-killed Mycobacterium leprae, or mixtures of the two were titrated in mice in doses of 10(5.2), 10(5.8), 10(6.4), 10(7.0), and 10(7.6) acid-fast bacilli. The immune response was measured by sensitization (48 to 72 h foot pad enlargement on challenge with 10(7.0) heat-killed M. leprae) and by protection against infection with a viable M. leprae challenge. There was increasing response with increasing dose of vaccine, and overall the responses to the three vaccines were similar. At the lowest dose, however, the combination of BCG and M. leprae gave superior protection. The local reaction to the vaccines in the lower dose range was less severe with the M. leprae vaccine. In another experiment, the three vaccines were compared in normal mice and in mice that had been rendered tolerant by intravenous injection of M. leprae. The tolerant mice developed no measurable sensitization on vaccination with M. leprae, but they developed partial but distinct sensitization on vaccination with BCG, alone or in combination with M. leprae. The tolerant mice developed little or no protection with any of the vaccines, however..(AU).
Descriptors:MYCOBACTERIUM LEPRAE/imunol
HANSENIASE/imunol
TOLERÂNCIA IMUNOLOGICA
VACINACAO
RELACAO DOSE-RESPOSTA IMUNOLOGICA
VACINAS BACTERIANAS/imunol
VACINA BCG/imunol
Limits:ESTUDO COMPARATIVO
ANIMAL
FEMININO
CAMUNDONGOS
SUPPORT, NON-U.S. GOV'T
Electronic Medium:http://www.ilsl.br
Location:BR191.1; 01555/s


  5 / 39 HANSEN  
              first record previous record next record last record
select
to print
Id:13456
Author:Shepard, Charles C; Walker, Laura L; Van Landingham, Rosalind
Title:Heat stability of Mycobacterium leprae immunogenicity ..-
Source:s.l; s.n; oct. 1978. 7 p. tab, graf.
Abstract:The protection provided to mice by vaccines administered intradermally was measured after footpad challenge with Mycobacterium leprae. The protection offered by M. leprae suspensions was not decreased when the vaccines were killed by 60 degrees C heat or at the higher temperatures tested, which included 215 degrees C (autoclave). Even highly purified suspensions retained their immunogenicity. In contrast, the vaccine protection provided by intradermal M. bovis (strain BCG) was markedly reduced when heated to 60 degrees C. The enlargement of the lymph nodes regional to the intradermal vaccines was measured and found generally to parallel the vaccine protection provided by M. leprae and by BCG.(AU).
Descriptors:MYCOBACTERIUM BOVIS
HANSENIASE/imunol
MYCOBACTERIUM LEPRAE/imunol
INJECOES SUBCUTÂNEAS
INJECOES INTRADERMICAS
VACINA BCG
IMUNIDADE CELULAR
VACINAS BACTERIANAS/admin
VACINAS BACTERIANAS/imunol
VACINAS BACTERIANAS/normas
CONGELAMENTO
 CALOR
Limits:ANIMAL
CAMUNDONGOS
SUPPORT, U.S. GOV'T, P.H.S.
Electronic Medium:http://www.ilsl.br
Location:BR191.1; 00293/s


  6 / 39 HANSEN  
              first record previous record next record last record
select
to print
Id:13380
Author:Shepard, Charles C; van Landingham, Rosalind; Walker, Laura L
Title:Searches among mycobacterial cultures for antileprosy vaccines ..-
Source:s.l; s.n; sep. 1980. 6 p. tab, graf.
Abstract:All mycobacteria species share some antigens, so there may be cultivable mycobacterial cultures that can provide vaccine protection against leprosy. Vaccine protection against Mycobacterium leprae infections in mice has been demonstrated for M. leprae itself, as living or heat-killed suspensions, and for Mycobacterium bovis (BCG), as living suspensions. Results are reported here with 17 other cultures. The mycobacterial suspensions were injected intradermally, and the mice were challenged in the footpad with infectious suspensions of M. leprae. In two experiments the mice were also challenged by footpad injections of 10(7) heat-killed M. leprae so the footpad enlargment could be measured. That some mycobacterial suspensions were immunogenic for some of their own antigens was suggested by reactions at the vaccine site and enlargement of the regional lymph nodes. Some mycobacterial suspensions also stimulated footpad enlargement on challenge by homologous suspensions or by challenge with M. leprae suspensions. Consistent protection against infectious challenge with M. leprae was observed only with BCG and M. leprae, however...(AU).
Descriptors:MYCOBACTERIUM/imunol
MYCOBACTERIUM BOVIS/imunol
LINFONODOS/imunol
HANSENIASE/prev
MYCOBACTERIUM LEPRAE/imunol
VACINAS BACTERIANAS/uso terap
VACINA BCG/uso terap
Limits:ANIMAL
FEMININO
CAMUNDONGOS
SUPPORT, NON-U.S. GOV'T
Electronic Medium:http://www.ilsl.br
Location:BR191.1; 01536/s


  7 / 39 HANSEN  
              first record previous record next record last record
select
to print
Id:13309
Author:Bhide, M. B; Dholam, S. B; Chatterjee, B. R
Title:Inhibition of foot pad multiplication of M. leprae in mice vaccinated with leproma derived M. leprae precursor coccoid organism and passive transfer of DTH response to normal mice through infusion of splenic cells of such vaccinated mice ..-
Source:s.l; s.n; oct. 1981. 8 p. graf.
Abstract:Inhibition of foot pad multiplication of M. leprae in mice vaccinated with leproma derived M. leprae precursor coccoid organism and passive transfer of DTH response to normal mice through infusion of splenic cells of such vaccinated mice.(AU).
Descriptors:VACINAS BACTERIANAS/imunol
HIPERSENSIBILIDADE TARDIA/imunol
IMUNIZACAO PASSIVA
MYCOBACTERIUM LEPRAE/imunol
BACO/transpl
VACINACAO
Limits:ANIMAL
CAMUNDONGOS
SUPPORT, NON-U.S. GOV'T
Electronic Medium:http://www.ilsl.br
Location:BR191.1; 00813/s


  8 / 39 HANSEN  
              first record previous record next record last record
select
to print
Id:12310
Author:Truoc, Le Van; Ly, Ho Minh; Thuy, Nguyen Kim; Trach, Dang Duc; Stanford, C. A; Stanford, J. L
Title:Vaccination against leprosy at Ben San Leprosy Center, Ho Chi Minh City, Vietnam ..-
Source:s.l; s.n; 2001. 8 p. tab.
Descriptors:ADOLESCENCIA
VACINA BCG
VACINAS BACTERIANAS
PRÉ-ESCOLAR
ESQUEMA DE IMUNIZAÇAO
HANSENIASE
HANSENIASE
HANSENIASE
HANSENIASE
MYCOBACTERIUM
TESTES CUTANEOS
FATORES DE TEMPO
VACINAS DE PRODUTOS INATIVADOS
VIETNA
Location:BR191.1; 08663/s


  9 / 39 HANSEN  
              first record previous record next record last record
select
to print
Id:12232
Author:Oliveira, Martha M; Charlab, Rosane; Pessolani, Maria Cristina V
Title:Mycobacterium bovis BCG but not mycobacterium leprae induces TNF-alpha secretion in human monocytic THP-1 cells ..-
Source:Rio de Janeiro; s.n; Oct. 2001. 6 p. tab, graf.
Descriptors:VACINA BCG
VACINAS BACTERIANAS
BOVINOS
HANSENIASE
MONOCITOS
MONOCITOS
MYCOBACTERIUM BOVIS
MYCOBACTERIUM LEPRAE
FATOR DE NECROSE TUMORAL/BI/*SE
CELULAS CULTIVADAS
Limits:ANIMAL
Location:BR191.1; 08634/s


  10 / 39 HANSEN  
              first record previous record next record last record
select
to print
Id:11615
Author:Truoc, Le Van; Ly, Ho Minh; Thuy, Nguyen Kim; Trach, Dang Duc; Stanford, C. A; Stanford, J. L
Title:Vaccination against leprosy at Ben San Leprosy Centre, Ho Chi Minh City, Vietnam ..-
Source:s.l; s.n; 2001. 8 p. tab.
Descriptors:MYCOBACTERIUM
VACINA BCG
VACINAS BACTERIANAS
ESQUEMA DE IMUNIZAÇAO
TESTES CUTANEOS
FATORES DE TEMPO
VACINAS DE PRODUTOS INATIVADOS
VIETNA
Location:BR191.1; 08438/s


  11 / 39 HANSEN  
              first record previous record next record last record
select
to print
Id:11594
Author:Martin, E; Roche, P. W; Triccas, J. A; Britton, W. J
Title:DNA encoding a single mycobacterial antigen protects against leprosy infection ..-
Source:s.l; s.n; 2001. 6 p. tab.
Descriptors:ANTIGENOS DE BACTÉRIAS
VACINA BCG
VACINAS BACTERIANAS
VACINAS BACTERIANAS
VACINAS BACTERIANAS
SEQUENCIA DE BASES
PRIMERS DO DNA
DNA BACTERIANO
DNA BACTERIANO
INTERFERON TIPO II
HANSENIASE
HANSENIASE
HANSENIASE
CAMUNDONGOS
MYCOBACTERIUM LEPRAE
MYCOBACTERIUM LEPRAE
LINFOCITOS T
VACINAS DE DNA/GE/IM/*PD
Limits:ANIMAL
Location:BR191.1; 08417/s


  12 / 39 HANSEN  
              first record previous record next record last record
select
to print
Id:11322
Author:Naito, Mariko; Matsuoka, Masanori; Ohara, Naoya; Nomaguchi, Hiroko; Yamada, Takeshi
Title:The antigen 85 complex vaccine against experimental mycobacterium leprae infection in mice ..-
Source:s.l; s.n; 2000. 4 p. tab, graf.
Descriptors:ANTIGENOS DE BACTÉRIAS
VACINAS BACTERIANAS
INTERFERON TIPO II
HANSENIASE
CAMUNDONGOS
CAMUNDONGOS ENDOGAMICOS BALB C
MYCOBACTERIUM LEPRAE
BAÇO
BAÇO
CAMUNDONGOS NUS
Limits:ANIMAL
Location:BR191.1; 07261/s


  13 / 39 HANSEN  
              first record previous record next record last record
select
to print
Id:11290
Author:Nath, Indira
Title:A vaccine for leprosy ..-
Source:s.l; s.n; 1998. 3 p. ilus, tab.
Descriptors:VACINAS BACTERIANAS
ENSAIOS CLINICOS
REAÇOES CRUZADAS
INDIA
HANSENIASE
MYCOBACTERIUM
VACINAÇAO
Location:BR191.1; 07229/s


  14 / 39 HANSEN  
              first record previous record next record last record
select
to print
Id:11034
Author:Yadava, Anjali; Mukherjee, Rama
Title:An immunodominant 30-kDa antigen of a candidate anti-leprosy vaccine, mycobacterium w, shares T and B cell determinants with m. leprae and m. tuberculosis ..-
Source:s.l; s.n; 1993. 11 p. ilus, graf.
Descriptors:HANSENIASE
MYCOBACTERIUM LEPRAE
MYCOBACTERIUM TUBERCULOSIS
ANTIGENOS DE BACTÉRIAS
ANTIGENOS DE BACTÉRIAS
LINFOCITOS B
VACINAS BACTERIANAS
COBAIAS
HIPERSENSIBILIDADE TARDIA
PESO MOLECULAR
LINFOCITOS T
Location:BR191.1; 07213/s


  15 / 39 HANSEN  
              first record previous record next record last record
select
to print
Id:11033
Author:Kaufmann, Stefan H. E; Young, Douglas B
Title:Vaccination against tuberculosis and leprosy ..-
Source:s.l; s.n; 1992. 22 p. .
Descriptors:HANSENIASE
ANTIGENOS DE BACTÉRIAS
VACINAS BACTERIANAS
IMUNIDADE CELULAR
MYCOBACTERIUM
TUBERCULOSE
Location:BR191.1; 07211/s


  16 / 39 HANSEN  
              first record previous record next record last record
select
to print
Id:11028
Author:Talwar, G. P
Title:An Immunotherapeutic vaccine for multibacillary leprosy ..-
Source:s.l; s.n; 1999. 21 p. ilus, graf.
Descriptors:VACINA BCG
VACINAS BACTERIANAS
VACINAS BACTERIANAS
ENSAIOS CLINICOS
HANSENIASE
MYCOBACTERIUM LEPRAE
TUBERCULOSE
Limits:ANIMAL
Location:BR191.1; 07460/s


  17 / 39 HANSEN  
              first record previous record next record last record
select
to print
Id:11023
Author:Mukhopadhyay, Asok; Panda, Amulya K; Pandey, Anil K
Title:Leprosy vaccine: influence of dissolved oxygen levels on growth of a candidate strain (mycobacterium w), and storage stability of the vaccine ..-
Source:s.l; s.n; 1998. 5 p. tab, graf.
Descriptors:VACINAS BACTERIANAS
VACINAS BACTERIANAS
TÉCNICAS BACTERIOLOGICAS
CATALASE
ESTABILIDADE DE MEDICAMENTOS
ARMAZENAGEM DE MEDICAMENTOS
HANSENIASE
MYCOBACTERIUM
MYCOBACTERIUM
MYCOBACTERIUM
CONSUMO DE OXIGENIO
SUPEROXIDO DISMUTASE
BIORREATORES
Location:BR191.1; 07280/s


  18 / 39 HANSEN  
              first record previous record next record last record
select
to print
Id:10331
Author:Jayaraman, K. S
Title:Charges fly over rival lleprosy vaccines ..-
Source:s.l; s.n; 1994. 1 p. ilus.
Descriptors:VACINAS BACTERIANAS
ENSAIOS CLINICOS
INDIA
HANSENIASE
HANSENIASE
MYCOBACTERIUM
MYCOBACTERIUM
Location:BR191.1; 07182/s


  19 / 39 HANSEN  
              first record previous record next record last record
select
to print
Id:10237
Author:Zaheer, S. Ahmed; Mukherjee, Rama; Ramkumar, Beena; Misra, Radhey S; Sharma, Amar K; Kar, Hemant K; Kaur, Harvinder; Nair, Sreekumaran; Mukherjee, Ashok; Talwar, Gursaran P
Title:Combined multidrug and mycobacterium w vaccine therapy in patients with multibacillary leprosy ..-
Source:s.l; s.n; 1993. 10 p. ilus, tab, graf.
Descriptors:VACINAS BACTERIANAS
QUIMIOTERAPIA COMBINADA
SEGUIMENTOS
IMUNOTERAPIA ATIVA
LEPROSTATICOS
HANSENIASE DIMORFA
HANSENIASE DIMORFA
HANSENIASE LEPROMATOSA
HANSENIASE LEPROMATOSA
MICOBACTERIOSE ATIPICA
PELE
RESULTADO DE TRATAMENTO
Location:BR191.1; 06938/s


  20 / 39 HANSEN  
              first record previous record
select
to print
Id:10231
Author:Gunby, Phil
Title:Can leprosy be neutralized by year 2000? ..-
Source:s.l; s.n; 1992. 1 p. .
Descriptors:VACINAS BACTERIANAS
HANSENIASE
MYCOBACTERIUM LEPRAE
OFLOXACINA
PREVALENCIA
RIFAMPINA
SAUDE MUNDIAL
Location:BR191.1; 06932/s



page 1 de 2 go to page        
   


Refine the search
  Database : HANSEN Advanced form   
Search for : Free form   

    Search in field  
1  
2
3
 
           



Search engine: iAH powered by WWWISIS

IAH - © BIREME/PAHO/WHO
Latin American and Caribbean Center on Health Sciences Information